262 related articles for article (PubMed ID: 34507111)
1. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
Zhou N; Velez MA; Bachrach B; Gukasyan J; Fares CM; Cummings AL; Lind-Lebuffe JP; Akingbemi WO; Li DY; Brodrick PM; Yessuf NM; Rettinger S; Grogan T; Rochigneux P; Goldman JW; Garon EB; Lisberg A
Lung Cancer; 2021 Nov; 161():34-41. PubMed ID: 34507111
[TBL] [Abstract][Full Text] [Related]
2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
3. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
4. Association between immune-related adverse event timing and treatment outcomes.
Hsiehchen D; Naqash AR; Espinoza M; Von Itzstein MS; Cortellini A; Ricciuti B; Owen DH; Laharwal M; Toi Y; Burke M; Xie Y; Gerber DE
Oncoimmunology; 2022; 11(1):2017162. PubMed ID: 35003896
[TBL] [Abstract][Full Text] [Related]
5. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
6. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
von Itzstein MS; Gonugunta AS; Wang Y; Sheffield T; Lu R; Ali S; Fattah FJ; Xie D; Cai J; Xie Y; Gerber DE
Cancer Immunol Immunother; 2022 Sep; 71(9):2169-2181. PubMed ID: 35072744
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
Zhao Z; Gao Y; Xue Q; Gao S; He J
Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
[TBL] [Abstract][Full Text] [Related]
8. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor.
Yu J; Xiong F; Xu Y; Xu H; Zhang X; Gao H; Li Y
Int Immunopharmacol; 2024 Jan; 127():111412. PubMed ID: 38160567
[TBL] [Abstract][Full Text] [Related]
9. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
10. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
11. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
12. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
[TBL] [Abstract][Full Text] [Related]
13. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
14. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Baumann P; Langer CJ
Clin Lung Cancer; 2021 Jan; 22(1):49-57. PubMed ID: 33250347
[TBL] [Abstract][Full Text] [Related]
16. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of immune checkpoint inhibitor therapy in patients with
Bhandari NR; Hess LM; Han Y; Zhu YE; Sireci AN
Immunotherapy; 2021 Aug; 13(11):893-904. PubMed ID: 34139897
[TBL] [Abstract][Full Text] [Related]
18. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
19. Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non-Small Cell Lung Cancer: A Single Institution Database Analysis.
Kobayashi H; Wakuda K; Naito T; Mamesaya N; Ko R; Ono A; Kenmotsu H; Murakami H; Shimizu T; Gon Y; Takahashi T
Clin Lung Cancer; 2023 Sep; 24(6):498-506.e3. PubMed ID: 37407292
[TBL] [Abstract][Full Text] [Related]
20. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.
Izawa N; Shiokawa H; Onuki R; Hamaji K; Morikawa K; Saji H; Ohashi H; Kasugai S; Hayakawa N; Ohara T; Sunakawa Y
ESMO Open; 2022 Apr; 7(2):100415. PubMed ID: 35247869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
